Diplomat Pharmacy (NYSE: DPLO) encountered significant headwinds in 2016, particularly with its hepatitis C business. The specialty pharmacy entered 2017 with much lower expectations.
The company reported its first-quarter 2017 results after the market closed on Monday. Did Diplomat meet its reduced expectations, or was another disappointing quarter in store? Here are the highlights.
Image source: Getty Images.